Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Q1 FY26 Earnings Presentation
21 slides from Alivus Life Sciences's earnings presentation, Aug 1, 2025
Slide 1: Exchange filing cover letter
August 01, 2025 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 R
Slide 2: Investor Presentation Q1 FY26
Investor Presentation Q1 FY26
Slide 3: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 4: Financial Performance Review
Financial Performance Review 3
Slide 5: Q1 FY26 Highlights
Q1 FY26 | Highlights "Our performance this quarter was primarily driven by strong growth in the Non-GPL business, which expanded by 14.5% YoY. Key regions including India (Ex-GPL), Europe, ROW, Dr. Yasir Rawjee LATAM, and Japan were major contributors to this growth. We remain confident of Managing
Slide 6: Q1 FY26 Performance
Q1 FY26 Performance Revenue EBITDA PAT EPS (In ₹ M illion) (In ₹ M illion) (In ₹ M illion) (In ₹) EBITDA Margin PAT Margin 21.3% 21.8% 6,496 6,418 20.2% 6,018 31.3% 32.1% 18.9% 18.8% 5,886 1,419 30.1% 1,370 11.57 28.0% 28.2% 11.18 2,085 2,008 5,069 1,215 1,813 9.91 1,115 1,650 9.10 953 1,429 7.78 Q1
Slide 7: P&L Highlights Q1 FY26
P&L Highlights | Q1 FY26 Particulars (In ₹ Million) Q1 FY26 Q4 FY25 QoQ Q1 FY25 YoY FY25 Revenue from Operations 6,018 6,496 -7.4% 5,886 2.2% 23,869 Gross Profit 3,315 3,670 -9.7% 3,008 10.2% 13,061 Gross Profit (%) 55.1% 56.5% -140 bps 51.1% 400 bps 54.7% Other Income 90 101 -10.9% 55 63.6% 346 Emp
Slide 8: Healthy Return Indicators
Healthy Return Indicators ROICE (%) Fixed Assets Turnover (Times) 40% 3.4 34% 2.9 32% 2.7 28% 2.5 2.4 27% FY22 FY23 FY24 FY25 Q1FY26 FY22 FY23 FY24 FY25 Q1FY26 • ROICE is tracking at ~28% – Capital employed driven by calibrated Capex strategy • FATR is 2.4 times – Asset turn trending slightly lower
Slide 9: Robust Growth & Steady Profitability
Robust Growth & Steady Profitability Revenue EBITDA PAT EPS (In ₹ Million ) (In ₹ M illion) (In ₹ M illion) (In ₹) EBITDA Margin PAT Margin 31.5… 31.4% 31.1% 21.6% 30.1% 30.0% 20.6% 20.3% 19.7% 39.63 38.43 38.11 7,172 4,857 6,863 23,869 4,709 6,712 35.63 4,670 18.6% 22,832 6,308 32.62 21,612 21,232
Slide 10: Business Performance Review
Business Performance Review 9
Slide 11: Segmental Performance: Generic API vs CDMO
Segmental Performance | Generic API vs CDMO Generic API CDMO (Revenue In ₹ M illio n) (Revenue In ₹ M illion) 5,966 5,941 425 434 5,517 5,354 360 300 4,739 240 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1FY26 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 • Generic API revenues in Q1FY26 saw a subtle • CDMO business
Slide 12: Segmental Performance: GPL vs Non-GPL
Segmental Performance | GPL vs Non-GPL GPL % of Total Revenue Non-GPL % of Total Revenue (In ₹ M illion) (In ₹ M illion) 37.2% 33.4% 33.6% 66.6% 72.4% 74.6% 66.4% 62.8% 27.6% 2,181 4,645 4,492 25.4% 4,315 1,963 1,888 3,923 1,773 1,526 3,181 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1FY26 Q1 FY25 Q2 FY25 Q3 F
Slide 13: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Mix 16% 13% 18% 14% 17% 32% 33% 30% 30% 39% Emerging Markets Acute 84% 87% 82% 86% 83% Regulated 68% 67% 70% 70% 61% Chronic Markets Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1 FY26 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 Q1FY26 • Regulated markets contributed 8
Slide 14: Company Overview
LIFE SCIENCES Company Overview ¢
Slide 15: Global Footprint
Global Footprint • Filed 569 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 70+ 370+ 30+ 115 147 176 10+ 19 125+ 10+ 50+ 22 90 (Brazil) India – Mix of Regulated Number of Number of customers As of June 30, 2025 R
Slide 16: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend (In ₹ M illion) North Therapy Europe Japan Brazil Australia ROW Total America % of Total Revenue CVS 39 40 4 23 10 41 157 CNS 42 26 8 17 3 21 117 3.4% 3.5% Anti-Infective 20 11 2 3 3 13 52 3.3% 3.0% Diabetes 10 5 - 9 - 15 39 2.7% 805 Dermatology 8
Slide 17: Quality Focused Manufacturing and R&D Infrastructure
Quality Focused Manufacturing and R&D Infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Last USFDA Location Approvals Mahape, Navi Mumbai Capacity Inspection Date USFDA, MHRA (UK), FIMEA ▪ R&D for new product (Finland), Romania (Europe) PMDA development and complex Ankl
Slide 18: Strategy Going Forward
LIFE SCIENCES Strategy Going Forward ¢
Slide 19: Strategy Growth Levers
Strategy Growth Levers 1 Gx API Business ✓ New product launches 2 ✓ Geographical expansion New Growth levers ✓ Focus on new markets becoming more regulated ✓ CDMO Ramp up ✓ Pursue 2nd source opportunities with top generic players ✓ Expand into complex API platforms 3 Capacity ✓ Iron compounds ✓ Onco
Slide 20: Future Capacity Expansion
Future Capacity Expansion Operational Expansion Type Division Location Status & Planned Capacity Timelines Brownfield API / Intermediate Ankleshwar Planned addition of ~100KL Capacity FY26 Brownfield API Dahej Planned addition of ~160KL FY26 Phase 1 – ~200 KL (Construction is in process) FY26 Greenf
Slide 21: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@alivus.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RUNJHUN JAIN SNEHA SALIAN Email: diwakar.pingle@in.ey.com Email: runjhun.jain1@in.ey.com Email: sneha2.salian@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68